Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

Archive

Newer Entries »

LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market Monday, February 12th, 2018

Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil [...]

Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten Wednesday, February 7th, 2018

Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster. The origins of Oncode go back [...]

LSP Life Sciences Fund makes 250% on Ablynx sale Wednesday, January 31st, 2018

To read the full article click here. [...]

Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations Friday, January 26th, 2018

Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda [...]

BioCapital Europe 2018, organised by LSP Friday, January 19th, 2018

BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]

LSP reaches milestone: 10 years investing in listed Life Sciences Securities Wednesday, January 17th, 2018

LSP Life Sciences Fund generates net return of 39% in 2017 Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li [...]

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis Thursday, January 11th, 2018

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will [...]

Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies Monday, January 8th, 2018

UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop an [...]

Takeda to acquire LSP portfolio company TiGenix Friday, January 5th, 2018

Takeda announces its intention to acquire TiGenix Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]

Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs Thursday, January 4th, 2018

- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country - UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a c [...]

Newer Entries »

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

back to archive overview

Archive

Archive

MONTHLY REPORTS